Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib in advanced pretreated SQCLC
NCT03762122Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jul 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rogaratinib in non-small cell lung cancer, squamous cell carcinoma (sqNSCLC), sponsored by Swiss Group for Clinical Cancer Research. Started Jul 2019; status: terminated.
02
Drugs
rogaratinib
03
Conditions
non-small cell lung cancer, squamous cell carcinoma (sqNSCLC)
Beyond the preview
Go deeper on NCT03762122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03762122.